Recent Price Movement and Market Context
On 4 Mar 2026, Lasa Supergenerics Ltd’s stock price touched Rs.7.13, its lowest level in the past year and also an all-time low. This decline comes after two consecutive days of losses, with the stock falling by 6.06% over this period. The day’s trading saw the stock underperform its sector by 1.95%, reflecting broader challenges within the Pharmaceuticals & Biotechnology industry. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market showed some resilience. The Sensex, after opening sharply lower by 1,710.03 points, recovered by 266.37 points to trade at 78,795.19, still down 1.8% on the day. However, the Sensex remains below its 50-day moving average, though the 50DMA is positioned above the 200DMA, indicating mixed technical signals at the index level.
Long-Term Performance and Relative Comparison
Over the last year, Lasa Supergenerics Ltd has experienced a steep decline of 64.73%, a stark contrast to the Sensex’s positive return of 7.98% during the same period. The stock’s 52-week high was Rs.24.44, highlighting the extent of the recent downturn. This underperformance is consistent with the company’s track record over the past three years, where it has lagged behind the BSE500 index annually.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Financial Health and Profitability Metrics
Lasa Supergenerics Ltd’s financial indicators reveal ongoing difficulties. The company reported net sales of Rs.5.26 crores over the latest six months, reflecting a sharp contraction of 92.74%. The quarterly profit after tax (PAT) stood at a loss of Rs.2.55 crores, down 17.3% compared to previous periods. These figures underscore the challenges in revenue generation and profitability.
The company’s return on equity (ROE) averages at 3.54%, indicating limited profitability relative to shareholders’ funds. Additionally, the EBIT to interest coverage ratio is negative at -5.16, signalling a weak capacity to service debt obligations. This financial strain contributes to the company’s current grading as a Strong Sell, an upgrade from its previous Sell rating as of 11 Feb 2025, according to MarketsMOJO’s assessment framework.
Valuation and Risk Profile
The stock’s valuation metrics further highlight its risk profile. Despite a 64.73% decline in share price over the past year, the company’s profits have increased by 101.8%, resulting in a price/earnings to growth (PEG) ratio of 1.4. This suggests that while earnings growth has been positive, it has not translated into share price appreciation, possibly due to concerns over sustainability and financial stability.
Lasa Supergenerics Ltd’s market capitalisation grade stands at 4, reflecting its relatively small size and associated liquidity considerations. The stock’s consistent underperformance against benchmarks such as the BSE500 over multiple years adds to the cautious outlook.
Shareholding and Sector Position
The company remains majority-owned by promoters, maintaining concentrated ownership. It operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance recently, with some indices such as NIFTY Realty and S&P BSE Realty hitting new 52-week lows on the same day, indicating sectoral volatility.
Holding Lasa Supergenerics Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns
The stock’s fall to Rs.7.13 reflects a combination of weak financial performance, limited profitability, and a challenging market environment. The company’s inability to generate positive EBIT interest coverage and its negative EBITDA position contribute to its classification as a Strong Sell. The persistent decline in net sales and quarterly losses further compound the cautious stance on the stock.
Despite some improvement in profits over the past year, the stock price has not responded favourably, indicating that market participants remain wary of the company’s fundamentals and growth prospects. The consistent underperformance relative to major indices and sector peers highlights the difficulties faced by Lasa Supergenerics Ltd in regaining investor confidence.
Market and Technical Indicators
Technically, the stock’s position below all major moving averages suggests continued downward pressure. The broader market’s partial recovery on the day contrasts with the stock’s weakness, emphasising company-specific factors driving the decline. The sector’s mixed performance, with some indices also hitting 52-week lows, adds to the overall cautious sentiment in the Pharmaceuticals & Biotechnology space.
Investors and analysts will likely continue to monitor the company’s financial disclosures and market developments closely, given the significant price erosion and fundamental challenges documented over the past year.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
